http://www.biospectator.com/view/news_view.php?varAtcId=18416
ABION (CEO Shin Young khee, KRX 203400) announced on the 6th that it will participate as a poster presenter at the American Thoracic Society (ATS) 2023, the largest thoracic conference in the United States.
ABION will present the results of the non-clinical trial of its viral respiratory inhalation therapy, ‘ABN101,’ at the ATS 2023, which will be held in Washington, D.C., from May 19th to 24th. ATS is a renowned conference with the highest attendance of respiratory specialists in the United States, where the latest clinical and research findings on major respiratory therapies and diseases are presented.
ABION has developed the next-generation interferon-beta, ‘ABN101,’ in dry powder inhaler (DPI) formulation optimized for the treatment of respiratory viral infections. The company administered ABN101 to primate animal models, monitored blood and bronchoalveolar lavage fluid, and obtained excellent pharmacokinetic results as well as both preventive and therapeutic effects. The interpretation indicates low systemic toxicity and a high target organ delivery rate of the drug. ABN101 has previously demonstrated preventive and therapeutic effects against coronaviruses (SARS-CoV-2 and variants), influenza viruses, and respiratory syncytial virus (RSV) through in vitro testing.
The development of a therapeutic drug that can preemptively address various respiratory viruses with a single medication is a strategic focus of global pharmaceutical companies. ABION aims to expedite the development of the antiviral treatment drug ‘ABN101’ by seizing opportunities in the current landscape.
ABION’s ‘ABN101’ is a next-generation interferon-beta that improves the material stability of conventional natural interferon-beta and increases production yield by over 500 times, enabling cost-effective research and production of various formulations. It has also been developed in dry powder formulation, confirming more than a three-fold increase in biological activity compared to the natural form. The company is currently developing ‘ABN101’ as a broad-spectrum antiviral drug.
An ABION representative stated, “Currently, the respiratory virus treatment drug ‘ABN101’ using dry powder inhaler holds a leading position in terms of cost and efficacy in the global market,” and added, “Based on the non-clinical results, we aim to enter full-scale clinical trials this year and actively engage in discussions with global pharmaceutical companies and technology exports.”
